Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pan-KRAS small interfering RNA
- Development stage
- Preclinical
- Lead developer
- EnFuego Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
A pan-KRAS small interfering RNA (siRNA) is a therapeutic oligonucleotide designed to silence the expression of the KRAS gene across its various isoforms and mutations. Unlike mutant-selective inhibitors, a pan-KRAS siRNA targets a conserved sequence within the KRAS mRNA to trigger its degradation via the RNA-induced silencing complex (RISC). This approach aims to inhibit the signaling of the KRAS protein, a critical GTPase involved in cell growth and survival that is frequently mutated in pancreatic, colorectal, and lung cancers. In preclinical research, such as that conducted by EnFuego Therapeutics, pan-KRAS siRNAs serve as potent tools to evaluate the impact of total KRAS knockdown compared to mutant-specific approaches like EFTX-G12V.
- Other names
- pan-KRAS siRNA
02
Targets
EGFR (Epidermal growth factor receptor)Kirsten rat sarcoma viral oncogene homolog mRNAMYC (MYC proto-oncogene protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on pan-KRAS small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pan-KRAS small interfering RNA.